News

Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech ...
The Manila Times2d
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results ...
Zealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetes
Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or ...
Pharmabiz7d
Zealand Pharma begins patient enrolment in phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes
Copenhagen, Denmark Saturday, April 26, 2025, 18:00 Hrs [IST] ...
The Manila Times10d
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal ...
Morningstar2d
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results
Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide ...
Morningstar10d
Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery
Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide ...